Is Enovix an Underrated Small Cap?
Enovix (NASDAQ:ENVX) is one of several small, innovative companies hoping…
Sell
43
SINT Quote, Financials, Valuation and Earnings
Last price:
$2.65
Seasonality move
:
11.64%
Day range:
$2.44 - $2.63
52-week range:
$1.71 - $45.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.62x
P/B ratio:
1.67x
Volume:
13.4K
Avg. volume:
76.1K
1-year change:
-70.37%
Market cap:
$6.5M
Revenue:
$1.2M
EPS (TTM):
-$33.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$725K | -$0.71 | 20.07% | -96.14% | $30.00 |
|
IVF
INVO Fertility
|
$1.6M | -- | -8.8% | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
$1.3M | -- | 157.41% | -57.14% | $1.45 |
|
NTRB
Nutriband
|
$665K | -$0.13 | 59.2% | -38.1% | $13.00 |
|
NVNO
enVVeno Medical
|
-- | -$0.34 | -- | -9.68% | $12.50 |
|
XAIR
Beyond Air
|
$1.4M | -- | 195.4% | -- | $2.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$2.59 | $30.00 | $6.5M | -- | $0.00 | 0% | 1.62x |
|
IVF
INVO Fertility
|
$2.09 | -- | $2.2M | -- | $0.00 | 0% | 0.11x |
|
NMTC
NeuroOne Medical Technologies
|
$0.62 | $1.45 | $19M | -- | $0.00 | 0% | 3.05x |
|
NTRB
Nutriband
|
$5.72 | $13.00 | $63.8M | -- | $0.00 | 0% | 28.36x |
|
NVNO
enVVeno Medical
|
$3.65 | $12.50 | $64M | -- | $0.00 | 0% | 356.07x |
|
XAIR
Beyond Air
|
$0.20 | $2.25 | $17.3M | -- | $0.00 | 0% | 3.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SINT
SINTX Technologies
|
0.82% | 0.321 | 0.68% | 1.91x |
|
IVF
INVO Fertility
|
-- | 3.433 | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
-- | -0.602 | -- | 2.23x |
|
NTRB
Nutriband
|
1.68% | 3.138 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | 0.246 | -- | -- |
|
XAIR
Beyond Air
|
0.34% | -0.284 | 0.22% | 2.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$38K | -$1.6M | -146.19% | -148.9% | -875.52% | -$1.3M |
|
IVF
INVO Fertility
|
-- | -- | -- | -- | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
$1.9M | $1.7M | -238.93% | -238.93% | 64.45% | $183.6K |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$5M | -- | -- | -- | -$4M |
|
XAIR
Beyond Air
|
-$215K | -$11M | -151.32% | -225.36% | -1192.54% | -$8.3M |
SINTX Technologies vs. Competitors
-
Which has Higher Returns SINT or IVF?
INVO Fertility has a net margin of -882.81% compared to SINTX Technologies's net margin of --. SINTX Technologies's return on equity of -148.9% beat INVO Fertility's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M IVFINVO Fertility-- -- -- -
What do Analysts Say About SINT or IVF?
SINTX Technologies has a consensus price target of $30.00, signalling upside risk potential of 1058.3%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 187.08%. Given that SINTX Technologies has higher upside potential than INVO Fertility, analysts believe SINTX Technologies is more attractive than INVO Fertility.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 1 0 IVFINVO Fertility0 0 0 -
Is SINT or IVF More Risky?
SINTX Technologies has a beta of 0.821, which suggesting that the stock is 17.937% less volatile than S&P 500. In comparison INVO Fertility has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.267%.
-
Which is a Better Dividend Stock SINT or IVF?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or IVF?
SINTX Technologies quarterly revenues are $192K, which are larger than INVO Fertility quarterly revenues of --. SINTX Technologies's net income of -$1.7M is higher than INVO Fertility's net income of --. Notably, SINTX Technologies's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.62x versus 0.11x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.62x -- $192K -$1.7M IVFINVO Fertility0.11x -- -- --
-
Which has Higher Returns SINT or NMTC?
NeuroOne Medical Technologies has a net margin of -882.81% compared to SINTX Technologies's net margin of 54.53%. SINTX Technologies's return on equity of -148.9% beat NeuroOne Medical Technologies's return on equity of -238.93%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M -
What do Analysts Say About SINT or NMTC?
SINTX Technologies has a consensus price target of $30.00, signalling upside risk potential of 1058.3%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 135.7%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 1 0 NMTCNeuroOne Medical Technologies1 0 0 -
Is SINT or NMTC More Risky?
SINTX Technologies has a beta of 0.821, which suggesting that the stock is 17.937% less volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.671%.
-
Which is a Better Dividend Stock SINT or NMTC?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NMTC?
SINTX Technologies quarterly revenues are $192K, which are smaller than NeuroOne Medical Technologies quarterly revenues of $3.3M. SINTX Technologies's net income of -$1.7M is lower than NeuroOne Medical Technologies's net income of $1.8M. Notably, SINTX Technologies's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.62x versus 3.05x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.62x -- $192K -$1.7M NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M
-
Which has Higher Returns SINT or NTRB?
Nutriband has a net margin of -882.81% compared to SINTX Technologies's net margin of -211%. SINTX Technologies's return on equity of -148.9% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About SINT or NTRB?
SINTX Technologies has a consensus price target of $30.00, signalling upside risk potential of 1058.3%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 127.27%. Given that SINTX Technologies has higher upside potential than Nutriband, analysts believe SINTX Technologies is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 1 0 NTRBNutriband1 0 0 -
Is SINT or NTRB More Risky?
SINTX Technologies has a beta of 0.821, which suggesting that the stock is 17.937% less volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.
-
Which is a Better Dividend Stock SINT or NTRB?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NTRB?
SINTX Technologies quarterly revenues are $192K, which are smaller than Nutriband quarterly revenues of $645.8K. SINTX Technologies's net income of -$1.7M is lower than Nutriband's net income of -$1.4M. Notably, SINTX Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.62x versus 28.36x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.62x -- $192K -$1.7M NTRBNutriband28.36x -- $645.8K -$1.4M
-
Which has Higher Returns SINT or NVNO?
enVVeno Medical has a net margin of -882.81% compared to SINTX Technologies's net margin of --. SINTX Technologies's return on equity of -148.9% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M NVNOenVVeno Medical-- -$0.22 -- -
What do Analysts Say About SINT or NVNO?
SINTX Technologies has a consensus price target of $30.00, signalling upside risk potential of 1058.3%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 242.47%. Given that SINTX Technologies has higher upside potential than enVVeno Medical, analysts believe SINTX Technologies is more attractive than enVVeno Medical.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 1 0 NVNOenVVeno Medical1 0 0 -
Is SINT or NVNO More Risky?
SINTX Technologies has a beta of 0.821, which suggesting that the stock is 17.937% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.726%.
-
Which is a Better Dividend Stock SINT or NVNO?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NVNO?
SINTX Technologies quarterly revenues are $192K, which are larger than enVVeno Medical quarterly revenues of --. SINTX Technologies's net income of -$1.7M is higher than enVVeno Medical's net income of -$4.5M. Notably, SINTX Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.62x versus 356.07x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.62x -- $192K -$1.7M NVNOenVVeno Medical356.07x -- -- -$4.5M
-
Which has Higher Returns SINT or XAIR?
Beyond Air has a net margin of -882.81% compared to SINTX Technologies's net margin of -1215.67%. SINTX Technologies's return on equity of -148.9% beat Beyond Air's return on equity of -225.36%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M XAIRBeyond Air-20.06% -$0.15 $18.4M -
What do Analysts Say About SINT or XAIR?
SINTX Technologies has a consensus price target of $30.00, signalling upside risk potential of 1058.3%. On the other hand Beyond Air has an analysts' consensus of $2.25 which suggests that it could grow by 1047.37%. Given that SINTX Technologies has higher upside potential than Beyond Air, analysts believe SINTX Technologies is more attractive than Beyond Air.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 1 0 XAIRBeyond Air1 1 0 -
Is SINT or XAIR More Risky?
SINTX Technologies has a beta of 0.821, which suggesting that the stock is 17.937% less volatile than S&P 500. In comparison Beyond Air has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75.019%.
-
Which is a Better Dividend Stock SINT or XAIR?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or XAIR?
SINTX Technologies quarterly revenues are $192K, which are smaller than Beyond Air quarterly revenues of $1.1M. SINTX Technologies's net income of -$1.7M is higher than Beyond Air's net income of -$13M. Notably, SINTX Technologies's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.62x versus 3.54x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.62x -- $192K -$1.7M XAIRBeyond Air3.54x -- $1.1M -$13M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Are We Heading Toward a Recession?
Fears of a recession in 2025 grew at the end…
3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 12
Regencell Bioscience Holdings [RGC] is up 36.61% over the past day.
Buy
97
NGVC alert for May 12
Natural Grocers by Vitamin Cottage [NGVC] is down 8.91% over the past day.
Sell
38
ONTO alert for May 12
Onto Innovation [ONTO] is up 4.94% over the past day.
